Bharat Biotech’s nasal Covid-19 vaccine gets DCGI approval

New Delhi, 6/9: The Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech’s intranasal Covid vaccine for restricted emergency use in those aged above 18 years.

 

“Big Boost to India’s Fight Against COVID-19! Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation,” Union Health Minister Mansukh Mandaviya tweeted.

Comments are closed.